Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
May 22, 2023
Previous PostMedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023
Next PostMedinCell announces the successful pricing of its Global Offering and raises €25 million
